a Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP , Paris , France.
b Department of Drug Development and Innovation (D3i), Institut Curie , Paris & Saint-Cloud , France.
Expert Opin Biol Ther. 2019 Sep;19(9):871-877. doi: 10.1080/14712598.2019.1646721. Epub 2019 Jul 23.
: The prognosis of patients with recurrent and/or metastatic cervical cancer remains poor, with a 5-year survival rate of 17%. Most of cervical cancers are associated with the human papillomavirus (HPV) infection that leads to viral antigens production, supporting the development of immunotherapy in cervical cancer. : Here we report the pharmacologic properties, clinical efficacy, and safety profile of pembrolizumab, an IgG4-kappa humanized monoclonal antibody against the programmed cell death protein 1 (PD-1) receptor, for the treatment of cervical cancer. : Single agent pembrolizumab has limited efficacy in the recurrent and/or metastatic setting in an unselected patient population. However, durable responses in PD-L1-expressing cervical cancer patients led the U.S. Food and Drug Administration to grant accelerated approval of pembrolizumab in this patient population. Outside this patient population, further development involves combinations with other treatment options including chemotherapy, radiotherapy and other immunotherapeutic agents. The identification of biomarkers of efficacy beyond PD-L1 expression will be essential in order to identify patients who will most likely benefit from pembrolizumab.
: 复发性和/或转移性宫颈癌患者的预后仍然较差，5 年生存率为 17%。大多数宫颈癌与人类乳头瘤病毒（HPV）感染有关，导致病毒抗原产生，支持宫颈癌的免疫治疗发展。 : 在这里，我们报告了 pembrolizumab 的药理特性、临床疗效和安全性，pembrolizumab 是一种针对程序性死亡蛋白 1（PD-1）受体的 IgG4-κ 人源化单克隆抗体，用于治疗宫颈癌。 : 在未选择的患者人群中，单药 pembrolizumab 在复发性和/或转移性环境中的疗效有限。然而，在 PD-L1 表达的宫颈癌患者中持久的反应促使美国食品和药物管理局加速批准 pembrolizumab 在这一患者群体中的应用。在这一患者群体之外，进一步的开发涉及与其他治疗方案的联合，包括化疗、放疗和其他免疫治疗药物。除了 PD-L1 表达之外，确定疗效的生物标志物将是至关重要的，以便确定最有可能从 pembrolizumab 中获益的患者。
